I have apt with Dr Vijay Ramanan coming Tuesday ( 29/9/15)
One thing want to share with u all..
http://www.ashg.org/genetics/ashg07s/f11147.htmTHALIDOMIDE THERAPY IN A PATIENT WITH THALASSEMIA MAJOR. L. Aguilar Lopez1, J.L. Delgado-Lamas1, B. Rubio1, F.J. Perea2,3, B. Ibarra2,3 1) Servicio de Hematologia, Hospital de Especialidades UMAE, CMNO, IMSS, Guadalajara, Mexico; 2) Division de Genetica, Centro de Investigacion Biomedica de Occidente, CMNO, IMSS Guadalajara Mexico; 3) Doctorado en Genética Humana, Universidad de Guadalajara, Guadalajara, Mexico.
The β thalassemia is characterized by a deficiency or absence of β globin chains. The homozygote state (Thalassemia Major), has high blood transfusion requirements since early age. We describe a 21 years old women with β Thalassemia Major diagnosed at 5 months of age. In 1997, the biochemical studies showed high HbF levels (62.3%) and HbA2 of 3.61%, the genotype was identified as -28 A-C/Cd 39 T-C. She had chronic blood transfusions, every 2 or 3 months, with an iron overload. She was splenectomized at the age of five years. She had received chelation therapy (Desferoxamina) with different time intervals. Her hemoglobin levels without transfusion were as low as 2.9 g/dL. The patient was received at the hematology service of the Hospital de Especialidades in Dcember 2001 with 4.0 g/dL, when she initiated the thalidomide therapy (100 mg per day), the first hemoglobin increase was observed after three moths to 7 g/dL, since then she has the thalidomide therapy uninterruptedly and never was transfused again with hemoglobin levels between 7.6 to 10.6 g/dL and almost 100% of HbF. She is at present in good health conditions with hemoglobin values of 10.2 g/dL. To our knowledge this is the first report of a Thalassemia Major patient treated with thalidomide with such a great results at the hemoglobin levels and general good health conditions. The molecular and physiological effects of the thalidomide must be deeply investigated, since it is know the angiogenic effect in cancer, the benefic effect in thalassemic patients could be mediated by its gene modulator effect however the true mechanism require to be investigated.